{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:36:53Z","timestamp":1773923813162,"version":"3.50.1"},"reference-count":41,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,3,20]]},"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the cost-effectiveness of adalimumab plus methotrexate (MTX) versus MTX monotherapy in early, aggressive rheumatoid arthritis (RA) when explicitly modelling short-term (reversible) and long-term (irreversible, ie, joint damage) disease activity and physical function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A microsimulation model was developed to unify, in a single cost-effectiveness model, measures of reversible and irreversible disease activity and physical function based on data from the PREMIER trial. Short term, reversible disease activity was modelled using DAS28 variables, including swollen joint counts, tender joint counts, C reactive protein concentration and pain. The DAS28 variables were then used in a logistic regression to predict short-term American College of Rheumatology (ACR) responses, which informed treatment continuation and switches. Long term, irreversible, radiographically documented joint damage was modelled using modified Total Sharp Score (mTSS). The model then linked both short-term disease activity and mTSS to the Health Assessment Questionnaire score, which was used to calculate direct and indirect costs, and quality adjusted life-years (QALYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When both reversible and irreversible effects of therapy were included, combination therapy was estimated to produce 6-month 50% ACR responses in 75% of patients versus 54% in MTX monotherapy. Compared to MTX monotherapy, combination therapy resulted in 2.68 and 3.04 discounted life years and QALYs gained, respectively. Combination therapy also resulted in a net increase in direct costs of \u00a3106\u2005207 for a resulting incremental cost\/QALY gain of \u00a332\u2005425. When indirect costs were included in the analysis, the ICER (incremental cost-effectiveness ratio) decreased to \u00a327\u2005238. Disregarding irreversible effects increased the incremental cost-effectiveness ratio to \u00a378\u2005809 (when only direct costs were included).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Starting with adalimumab plus MTX combination therapy in early, aggressive RA is cost-effective when irreversible damage is adequately considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-006560","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T16:06:43Z","timestamp":1433952403000},"page":"e006560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease"],"prefix":"10.1136","volume":"5","author":[{"given":"Stephanie","family":"Stephens","sequence":"first","affiliation":[{"name":"Pharmerit Ltd, York, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc F","family":"Botteman","sequence":"additional","affiliation":[{"name":"Pharmerit North America, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A","family":"Cifaldi","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben A","family":"van Hout","sequence":"additional","affiliation":[{"name":"Pharmerit Ltd, York, UK"},{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"2025121300271992000_5.6.e006560.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06075-5"},{"key":"2025121300271992000_5.6.e006560.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.5.453"},{"key":"2025121300271992000_5.6.e006560.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.22052"},{"key":"2025121300271992000_5.6.e006560.4","first-page":"1792","article-title":"Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)","volume":"22","author":"van der Heijde","year":"1995","journal-title":"J Rheumatol"},{"key":"2025121300271992000_5.6.e006560.5","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R"},{"key":"2025121300271992000_5.6.e006560.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1367"},{"key":"2025121300271992000_5.6.e006560.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"2025121300271992000_5.6.e006560.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"2025121300271992000_5.6.e006560.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200354"},{"key":"2025121300271992000_5.6.e006560.10","unstructured":"HUMIRA [prescribing information]. North Chicago, IL: Abbott Laboratories, 2011. http:\/\/www.rxabbott.com\/pdf\/humira.pdf (accessed 26 Apr 2012)."},{"key":"2025121300271992000_5.6.e006560.11","unstructured":"Enbrel [prescribing information]. Thousand Oaks, CA: Immunex Corporation, 2011. pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf (accessed 26 Apr 2012)."},{"key":"2025121300271992000_5.6.e006560.12","unstructured":"Remicade [prescribing information]. Malvern, PA: Centocor, 2011. http:\/\/www.remicade.com\/remicade\/assets\/HCP_PPI.pdf (Accessed 26 Apr 2012)."},{"key":"2025121300271992000_5.6.e006560.13","unstructured":"Simponi [prescribing information]. Horsham, PA: Janssen Biotech, Inc., 2011. http:\/\/www.simponi.com\/sites\/default\/files\/pdf\/prescribing-information.pdf (accessed 26 Apr 2012)."},{"key":"2025121300271992000_5.6.e006560.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"2025121300271992000_5.6.e006560.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"2025121300271992000_5.6.e006560.16","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f5fcf6"},{"key":"2025121300271992000_5.6.e006560.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"2025121300271992000_5.6.e006560.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"2025121300271992000_5.6.e006560.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"2025121300271992000_5.6.e006560.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"2025121300271992000_5.6.e006560.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"2025121300271992000_5.6.e006560.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"key":"2025121300271992000_5.6.e006560.23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2165\/00019053-200624120-00006","article-title":"Cost effectiveness of tumor necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis","volume":"24","author":"Spalding","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"2025121300271992000_5.6.e006560.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080257"},{"key":"2025121300271992000_5.6.e006560.25","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462311000195"},{"key":"2025121300271992000_5.6.e006560.26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-9-200911030-00006"},{"key":"2025121300271992000_5.6.e006560.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.24169"},{"key":"2025121300271992000_5.6.e006560.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker084"},{"key":"2025121300271992000_5.6.e006560.29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40273-014-0184-4","article-title":"Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis","volume":"32","author":"Tran-Duy","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2025121300271992000_5.6.e006560.30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20072"},{"key":"2025121300271992000_5.6.e006560.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.9.793"},{"key":"2025121300271992000_5.6.e006560.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009530"},{"key":"2025121300271992000_5.6.e006560.33","unstructured":"Bojke C , Cifaldi M , Ray S , et al . Impact of maintaining physical function on employment status over time. Abstract presented at: ACR\/ARHP Scientific Meeting; October 17\u201321, 2009; Philadelphia, PA."},{"key":"2025121300271992000_5.6.e006560.34","unstructured":"British National Formulary [Internet]. http:\/\/www.bnf.org (accessed 14 Jan 2014)."},{"key":"2025121300271992000_5.6.e006560.35","unstructured":"Personal Social Services Research. Unit costs of health and social care 2010 [Internet]. http:\/\/www.pssru.ac.uk\/uc\/uc2010contents.htm (accessed 26 Apr 2012)."},{"key":"2025121300271992000_5.6.e006560.36","unstructured":"Personal Social Services Research. Unit costs of health and social care 2012 [Internet]. http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2012\/ (accessed 14 Jan 2014)."},{"key":"2025121300271992000_5.6.e006560.37","unstructured":"Office for National Statistics. EARN01: Average Weekly Earnings (AWE), seasonally adjusted [Internet]. http:\/\/www.ons.gov.uk\/ons\/rel\/lms\/labour-market-statistics\/december-2013\/tableearn01.xls (accessed 14 Jan 2014)."},{"key":"2025121300271992000_5.6.e006560.38","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal [Internet]. http:\/\/www.nice.org.uk\/media\/D45\/1E\/GuideToMethodsTechnologyAppraisal2013.pdf (accessed 14 Jan 2014)."},{"key":"2025121300271992000_5.6.e006560.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093294"},{"key":"2025121300271992000_5.6.e006560.40","unstructured":"National Institute for Health and Care Excellence (NICE) Clinical Guideline CG79 Rheumatoid arthritis [Internet]. http:\/\/guidance.nice.org.uk\/CG79\/NICEGuidance\/pdf\/English (accessed 19 Mar 2014)."},{"key":"2025121300271992000_5.6.e006560.41","unstructured":"DAS28\u2014Home of the Disease activity score and DAS28 [Internet]. Radboud University Nijmegen Medical Centre. http:\/\/www.das-score.nl\/das28\/en\/difference-between-the-das-and-das28\/das-28-indepth.html (accessed 19 Mar 2014)."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-006560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:27:29Z","timestamp":1765614449000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-006560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,9]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1136\/bmjopen-2014-006560"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-006560","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}